A Study to Learn How Men With Advanced Prostate Cancer Respond to Treatment With Darolutamide and Hormone Therapy, With or Without Chemotherapy, in Real-world Medical Practice
Male aged ≥18 years (or country's legal age of adulthood if \>18 years)
Histologically or cytologically confirmed adenocarcinoma of prostate; may have begun ADT (up to 120 days prior to enrollment)
Metastatic disease by conventional or new generation imaging
Decision to initiate treatment with darolutamide with or without docetaxel made prior to enrollment
Signed informed patient consent before start of data collection
Life expectancy of ≥3 months based on clinical judgment
You may not be if
Participation in an investigational program with interventions outside of routine clinical practice
Contraindications according to local marketing authorization
Any prior treatment with second-generation androgen receptor (AR) inhibitors such as enzalutamide, apalutamide, or other investigational AR inhibitors, cytochrome P17 enzyme inhibitor (except prior abiraterone acetate if discontinued at least 24 months before metastatic diagnosis) or other investigational CYP 17 enzyme inhibitors as antineoplastic treatment for prostate cancer.
Prior hormone therapy in the metastatic setting
Treatment with darolutamide initiated more than 7 days prior to enrollment
Clareo Health | A Study to Learn How Men With Advanced Prostate Cancer Respond to Treatment With Darolutamide and Hormone Therapy, With or Without Chemotherapy, in Real-world Medical Practice
